Fig. 6

RB1 Mechanism in cSCLC. A Association between RB1 VAF and immune score; B wGII between wild-type RB1 and mutant-type RB1 in the whole cohort; C wGII in SCLC-ADC/SCLC subtypes; D Heatmap of DDR gene expression; E Likelihood of occurring neoantigen expressed in tumors with wild-type RB1 and mutant-type RB1; F Likelihood of generating neoantigen in consistently expressed genes in tumors with wild-type RB1 and mutant-type RB1; G Likelihood of neoantigen occurring in all copy number loss regions in tumors with wild-type RB1 and mutant-type RB1; H Likelihood of neoantigen occurring in clonal copy number loss regions in tumors with wild-type RB1 and mutant-type RB1; I Likelihood of neoantigen occurring in subclonal copy number loss regions in tumors with wild-type RB1 and mutant-type RB1; J Enrichment score of cytokine production; K Chronic inflammatory response up; L Acute inflammatory response up pathways between wild-type RB1 and mutant-type RB1; M Influence of RB1 alteration status on TIME